← Back to Search

BOLSTER for Gastrointestinal Cancer

N/A
Waitlist Available
Led By Alexi A Wright, MD, MPH
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
GYN or GI cancers receiving anti-neoplastic therapy
Cognitive impairment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Study Summary

This trial is testing a new program, BOLSTER, to see if it can provide more support for patients with gynecologic or gastrointestinal cancers and their caregivers after a hospital stay.

Eligible Conditions
  • Gynecologic Cancers
  • Gastrointestinal Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are currently receiving anti-cancer treatment for gastrointestinal or gynecological cancers.
Select...
You have difficulty thinking or remembering things clearly.
Select...
You are a family member or friend of someone who is eligible to participate in the trial.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility of the BOLSTER Intervention
Secondary outcome measures
Acceptability of the BOLSTER Intervention

Trial Design

2Treatment groups
Experimental Treatment
Group I: Enhanced Discharge Planning (EDP)Experimental Treatment1 Intervention
Medication education, Self-management strategies for symptoms, Skills training, A list of red flag symptoms and numbers for who to call
Group II: BolsterExperimental Treatment1 Intervention
Bolster provides participants with longitudinal nursing support across care settings, A smartphone-based symptom management app, A print and web-based symptom management toolkit, Advance care planning to ensure that the patient receives care that is congruent with her informed preferences BOLSTER includes a total of 6 contacts with a study nurse over 4 weeks Daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BOLSTER
2018
N/A
~130

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,613 Previous Clinical Trials
40,918,184 Total Patients Enrolled
Dana-Farber Cancer InstituteLead Sponsor
1,072 Previous Clinical Trials
340,247 Total Patients Enrolled
Alexi A Wright, MD, MPHPrincipal InvestigatorDana-Farber Cancer Institute
2 Previous Clinical Trials
70 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies available for participants in this research trial?

"According to clinicaltrials.gov, this experiment is not presently enrolling participants. It was initially posted on April 24th 2018 and had its last update on July 28th 2022. Though it's no longer recruiting, there are still 845 other trials that have open slots for volunteers."

Answered by AI
~17 spots leftby Mar 2025